Affordable Access

Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells.

Publication Date
  • Biotinylation
  • Bone Neoplasms/Metabolism/Secondary
  • Bone And Bones
  • Breast Neoplasms/Metabolism/Pathology
  • Cell Line
  • Tumor
  • Cell Membrane
  • Female
  • Gene Expression
  • Gene Expression Regulation
  • Neoplastic
  • Humans
  • Mass Spectrometry
  • Proteome/Metabolism
  • Life Sciences :: Biochemistry
  • Biophysics & Molecular Biology [F05]
  • Sciences Du Vivant :: Biochimie
  • Biophysique & Biologie Moléculaire [F05]
  • Human Health Sciences :: Oncology [D15]
  • Sciences De La Santé Humaine :: Oncologie [D15]
  • Biology
  • Medicine


Metastatic breast cancer cells are characterized by their high propensity to colonize the skeleton and form bone metastases, causing major morbidity and mortality. Identifying key proteins involved in the osteotropic phenotype would represent a major step toward the development of both new prognostic markers and new effective therapies. Cell surface proteins differentially expressed in cancer cells are preferred potential targets for antibody-based targeted therapies. In this study, using cell surface biotinylation and a mass spectrometric approach, we have compared the profile of accessible cell surface proteins between the human breast cancer cell line MDA-MB-231 and its highly osteotropic B02 subclone. This strategy allowed the identification of several proteins either up- or downregulated in the osteotropic cell line, and differential protein expressions were validated using antibody-based techniques. Class I HLAs were down-regulated in the bone metastatic variant, whereas alpha(v)beta(3) integrins, among others, were consistently up-regulated in this latter cell line. These results show that comprehensive profiling of the cell surface proteome of mother cancerous cell lines and derived organ-specific metastatic cell lines provides an effective approach for the identification of potential accessible marker proteins for both prognosis and antibody-based targeted therapies.

There are no comments yet on this publication. Be the first to share your thoughts.